12:00 AM
 | 
Jan 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AP1903: Began Phase II testing

Ariad Pharmaceuticals Inc. (ARIA), Cambridge, Mass.
Product: AP1903
Business: Gene/Cell therapy
Therapeutic category: Gene therapy
Target: Transplanted T cells...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >